KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Debt to Equity (2017 - 2025)

Amneal Pharmaceuticals has reported Debt to Equity over the past 9 years, most recently at -$36.23 for Q4 2025.

  • Quarterly results put Debt to Equity at -$36.23 for Q4 2025, down 65.93% from a year ago — trailing twelve months through Dec 2025 was -$36.23 (down 65.93% YoY), and the annual figure for FY2025 was -$36.23, down 65.93%.
  • Debt to Equity for Q4 2025 was -$36.23 at Amneal Pharmaceuticals, down from -$23.41 in the prior quarter.
  • Over the last five years, Debt to Equity for AMRX hit a ceiling of $128.18 in Q4 2023 and a floor of -$41.79 in Q2 2024.
  • Median Debt to Equity over the past 5 years was $0.17 (2021), compared with a mean of -$0.35.
  • Biggest five-year swings in Debt to Equity: soared 11268.73% in 2023 and later crashed 336.08% in 2024.
  • Amneal Pharmaceuticals' Debt to Equity stood at $0.23 in 2021, then surged by 5988.37% to $14.25 in 2022, then skyrocketed by 799.42% to $128.18 in 2023, then crashed by 117.04% to -$21.84 in 2024, then tumbled by 65.93% to -$36.23 in 2025.
  • The last three reported values for Debt to Equity were -$36.23 (Q4 2025), -$23.41 (Q3 2025), and -$19.35 (Q2 2025) per Business Quant data.